- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging biologics in inflammatory bowel disease
Authors
Keywords
Crohn’s disease, Ulcerative colitis, Biologics, Biosimilar
Journal
JOURNAL OF GASTROENTEROLOGY
Volume 52, Issue 2, Pages 141-150
Publisher
Springer Nature
Online
2016-11-10
DOI
10.1007/s00535-016-1283-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease
- (2016) G. Monteleone et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium
- (2016) Parambir S Dulai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region
- (2016) Heyson C. H. Chan et al. BMC GASTROENTEROLOGY
- Long-term Outcomes of Thalidomide Therapy for Adults With Refractory Crohn’s Disease
- (2016) Marion Simon et al. Clinical Gastroenterology and Hepatology
- Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents
- (2016) Pauline Wils et al. Clinical Gastroenterology and Hepatology
- Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia
- (2016) Siew C. Ng et al. GASTROENTEROLOGY
- The safety of vedolizumab for ulcerative colitis and Crohn's disease
- (2016) Jean-Frédéric Colombel et al. GUT
- Biosimilars in Crohnʼs Disease and Ulcerative Colitis
- (2016) Douglas C. Wolf INFLAMMATORY BOWEL DISEASES
- Ustekinumab for the Treatment of Refractory Crohnʼs Disease
- (2016) Sam Khorrami et al. INFLAMMATORY BOWEL DISEASES
- Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis
- (2016) Julian Panés et al. Journal of Crohns & Colitis
- Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients
- (2016) Jørgen Jahnsen Therapeutic Advances in Gastroenterology
- Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes
- (2015) Julián Panés et al. BMC GASTROENTEROLOGY
- Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
- (2015) R.G. Langley et al. BRITISH JOURNAL OF DERMATOLOGY
- Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
- (2015) Henit Yanai et al. Clinical Gastroenterology and Hepatology
- Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single center
- (2015) Klaudia Farkas et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort
- (2015) Krisztina B. Gecse et al. Journal of Crohns & Colitis
- Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations
- (2015) J. Sieczkowska et al. Journal of Crohns & Colitis
- Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
- (2015) Yoon Suk Jung et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Biologic agents for IBD: practical insights
- (2015) Silvio Danese et al. Nature Reviews Gastroenterology & Hepatology
- Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
- (2015) Giovanni Monteleone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased risk of mycobacterial infections associated with anti-rheumatic medications
- (2015) S. K. Brode et al. THORAX
- Association between tumour necrosis factor- inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study
- (2015) N. Nyboe Andersen et al. BMJ-British Medical Journal
- Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea
- (2015) Sang Hyoung Park et al. Expert Review of Gastroenterology & Hepatology
- Association between tumour necrosis factor- inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study
- (2015) N. Nyboe Andersen et al. BMJ-British Medical Journal
- Long-term outcomes of thalidomide in refractory Crohn's disease
- (2014) M. E. Gerich et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The biosimilar road in inflammatory bowel disease: The right way?
- (2014) Gionata Fiorino et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
- (2014) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
- (2014) Bruce E. Sands et al. GASTROENTEROLOGY
- Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases
- (2013) M. Rinaudo-Gaujous et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Infectious and Malignant Complications of TNF Inhibitor Therapy in IBD
- (2013) Laura E Targownik et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Incidence and Phenotype of Inflammatory Bowel Disease Based on Results From the Asia-Pacific Crohn's and Colitis Epidemiology Study
- (2013) Siew C. Ng et al. GASTROENTEROLOGY
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Effect of Thalidomide on Clinical Remission in Children and Adolescents With Refractory Crohn Disease
- (2013) Marzia Lazzerini et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: A retrospective study
- (2013) Mei Lan Huang et al. Journal of Crohns & Colitis
- Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: A prospective population-based study
- (2013) Zhirong Zeng et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype
- (2013) Catherine Milch et al. JOURNAL OF NEUROIMMUNOLOGY
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease
- (2013) Mehmet Coskun et al. PHARMACOLOGICAL RESEARCH
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
- (2012) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: A retrospective analysis of 49 cases
- (2012) Han Hee Ryu et al. CLINICAL RHEUMATOLOGY
- Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study
- (2012) Mirthe Emilie van der Valk et al. GUT
- Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates
- (2012) Eric R. Fedyk et al. INFLAMMATORY BOWEL DISEASES
- Management of inflammatory bowel disease in pregnancy
- (2012) Séverine Vermeire et al. Journal of Crohns & Colitis
- Crohn's disease
- (2012) Daniel C Baumgart et al. LANCET
- Discovery and mechanism of ustekinumab
- (2012) Jacqueline M. Benson et al. mAbs
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing Response and Loss of Response to Biological Therapies in IBD
- (2011) Henit Yanai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
- (2011) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Deciphering the mystery of thalidomide teratogenicity
- (2011) Takumi Ito et al. CONGENITAL ANOMALIES
- Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
- (2011) Jean Frédéric Colombel et al. GASTROENTEROLOGY
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
- (2011) W. Reinisch et al. GUT
- Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease
- (2011) James H. Kim et al. TOXICOLOGICAL SCIENCES
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures
- (2010) S. M. MCHUGH et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy
- (2010) C. Loras et al. GUT
- Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States
- (2010) K. T. Park et al. INFLAMMATORY BOWEL DISEASES
- Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection
- (2010) Mark E. Flanagan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
- (2010) David B Clifford et al. LANCET NEUROLOGY
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diverse Genome-wide Association Studies Associate the IL12/IL23 Pathway with Crohn Disease
- (2009) Kai Wang et al. AMERICAN JOURNAL OF HUMAN GENETICS
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
- (2009) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
- (2009) Corey A. Siegel et al. Clinical Gastroenterology and Hepatology
- Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease
- (2009) Fabian Schnitzler et al. INFLAMMATORY BOWEL DISEASES
- Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis
- (2009) Mary G. Boy et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
- (2009) D. Soler et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
- (2008) William J. Sandborn et al. GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started